Gilead’s Livdelzi Meets ALP Normalization Endpoint in 75.4% of Phase 3 PBC Trial Patients
Gilead said Livdelzi met the ALP normalization endpoint in 75.4% of patients in a Phase 3 trial for PBC.
Related stories
Lam Research Authorizes $25 Billion Share Repurchase
The board approved a $25 billion buyback authorization with no termination date. Shares rose 10% to $204.12 by midday Friday and were up 19% this year.
M impact | EQUITY | Nov 06, 2026, 04:57 PM UTC
cBrain Holds Q3 2026 Earnings Call
cBrain held its Q3 2026 earnings call on November 6, 2026.
M impact | EQUITY | Nov 06, 2026, 04:33 PM UTC
ChemoMetec Reports Q1 Revenue Growth and DKK 100.3M EBITDA
Revenue in ChemoMetec’s core LCB business rose 31% year over year in Q1 2026/27, accounting for 96% of total revenue. EBITDA was DKK 100.3 million, with a 63% margin versus 55% a y
M impact | EQUITY | Nov 06, 2026, 04:32 PM UTC
US session market picture: S&P 500 +0.64%, Nasdaq 100 +1.47%; EUR/USD -0.6%, WTI -0.1%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.64 percent, Nasdaq futures is up 1.47 percent, Dow futures is down 0.06 percent and Russell futures is up 0.43
M impact | EQUITY | Nov 06, 2026, 04:32 PM UTC
TTK Prestige Q2 Profit Rises 65% to ₹104.4 Crore
Consolidated net profit increased from ₹63.2 crore a year earlier. Revenue from operations rose 21% year on year to ₹1,008.96 crore.
M impact | EQUITY | Nov 06, 2026, 04:21 PM UTC
Strive Reports $509 Million Q3 Profit on Bitcoin Gains
Strive reported $509 million in third-quarter net income, driven by $533.7 million in unrealized gains on its bitcoin holdings. Diluted earnings were $5.24 per share.
M impact | EQUITY | Nov 06, 2026, 04:11 PM UTC